Enamel matrix derivative (EMD), an extract of fetal porcine enamel, and TGF-b can both suppress adipogenic differentiation. However, there have been no studies that functionally link the role of EMD and TGF-b in vitro. Herein, we examined whether TGF-b signaling contributes to EMD-induced suppression of adipogenic differentiation. Adipogenesis was studied with 3T3-L1 preadipocytes in the presence of SB431542, an inhibitor of TGF-bRI kinase activity. SB431542 reversed the inhibitory effect of EMD on adipogenic differentiation, based on Oil Red O staining and mRNA expression of lipid regulated genes. SB431542 also reduced EMD-stimulated expression of connective tissue growth factor (CTGF), an autocrine inhibitor of adipogenic differentiation. Moreover, short interfering (si)RNAs for CTGF partially reversed the EMD-induced suppression of lipid regulated genes. We conclude that the TGF-bRI -CTGF axis is involved in the anti-adipogenic effects of EMD in vitro.
Introduction
EmdogainH is the commercial name for the combination of enamel matrix derivatives (EMD) isolated from the tooth germs of 6-month old piglets and the vehicle propylene glycol alginate (PGA) (Institut Straumann, Basel, Switzerland, formerly Biora, Malmö, Sweden). EmdogainH is approved to support periodontal tissue regeneration [1] . Histological and clinical data have indicated that the use of EmdogainH in combination with palatal subepithelial connective tissue grafts (CTG) may enhance periodontal wound healing/regeneration and to additionally improve the clinical outcomes when compared to the use of CTG alone [2] [3] [4] . Periodontal tissues and connective tissue grafts both contain mesenchymal cells that can become adipocytes [5] [6] [7] . However, adipogenic differentiation is unwanted when a regain of periodontal structures or the formation of a collagen-rich matrix is desired, respectively. A first clue that EmdogainH can suppress adipogenic differentiation comes from in vitro studies with the mouse multipotent myoblast cell line C2C12 [8] and periodontal ligament fibroblasts [6] . The underlying cellular mechanisms however are poorly defined [9, 10] .
Transforming growth factor-beta1 (TGF-b) signaling is among the key mechanisms that can mediate at least part of the in vitro cellular responses to EMD and EmdogainH [11] [12] [13] [14] . Recombinant TGF-b inhibits adipocyte differentiation as exemplified by the suppression of lipid droplets and the expression of adipogenic genes such as peroxisome proliferator-activated receptor c (PPARc), fatty acid binding protein 4 (FABP4), thrombospondin receptor (CD36), and leukotriene C4 synthase (LTC4s) in the preadipogenic 3T3-L1 clonal cell line [15, 16] . TGF-b binding to type I and type II receptor kinases (TGF-bR) activates Smad2 and Smad3 signaling [17] . TGF-bR can also signal through mitogenactivated protein kinases, including ERK, c-Jun N-terminal kinase (JNK) and p38, as well the PI3K pathway [18] . Smad [19] and mitogen-activated protein kinase [20] signaling are involved in TGF-b -mediated inhibition of adipogenesis. Also EMD can activate signaling via Smad2 and JNK [21] . Together, these data led to the hypothesis that the suppression of adipogenic differentiation by EMD may involve TGF-b signaling.
Consistent with this hypothesis is that both, TGF-b and EmdogainH increase the expression of connective tissue growth factor (CTGF) also known as CCN2 [14, 22, 23] . CTGF inhibits adipocyte differentiation [23] and CTGF can mediate the cellular responses to TGF-b, including the inhibition of adipocyte differentiation [16] . Moreover, enamel matrix derivative can also increase CTGF expression via TGF-b activity in osteoblastic cells [14] . SB431542, a TGF-b receptor antagonist and a JNK antagonist can inhibit CTGF expression induced by TGF-b1 in fibroblasts [24, 25] . It is thus reasonable to hypothesize that the expected suppression of adipogenic differentiation by EMD requires TGF-b signaling and involves CTGF expression. Therefore, the aim of this study was to test this hypothesis by means of the pre-adipogenic 3T3-L1 cell line.
Materials and Methods

Adipogenic Differentiation
The 3T3-L1 murine preadipocyte cell line was kindly donated by Christian Wolfrum ( [26] ; ETH Zürich, Switzerland) and cultured in a humidified atmosphere at 37uC in growth medium consisting of DMEM (Invitrogen Corporation, Carlsbad, CA, USA), 10% fetal calf serum (FCS; Invitrogen) and antibiotics (Invitrogen). Mouse subcutaneous adipose tissue was obtained from the inguinal region and cells were isolated by 0.1% collagenase I (Sigma) digestion. Cells were plated in growth medium at 30,000 cells/cm2 into culture dishes. The following day, cells were incubated in growth medium containing 0.5 mM 1-methyl-3-isobutyl-xanthine (Sigma), 1 mM dexamethasone (Sigma) and 1 mg/ml insulin (Calbiochem, Merck Millipore; MA). To further stimulate adipogenesis, 10 mM indomethacin (Sigma) and 10 mM rosiglitazone (Sigma) were added to the growth medium [27] . If not otherwise indicated, cells were cultivated for 5 days.
Test Compounds
Cells were incubated with EmdogainH at dilutions equivalent to 100 mg EMD/ml or the respective carrier propylene glycol alginate (PGA; kindly provided by Dr. Graf; Institut Straumann AG, Basel, Switzerland). EmdogainH containing 30 mg enamel matrix derivative (EMD)/ml PGA (approximately 6,5% wt. PGA, pH 3.7) and the respective vehicle were dissolved in serum-free medium to 10 mg EMD/ml and kept a 4uC for further dilution. For indicated experiments, EmdogainH (10 mg/ml) was heat treated at 96uC for 3 min [28] . 3T3-L1 cells were also exposed to EmdogainH and TGF-b for 24 hours before further cultivation in adipogenic medium. Recombinant human (rh) TGF-b1 was purchased from Prospec (Ness-Ziona, Israel). SB431542 (TGF-b receptor antagonist; IC50 = 94 nM) and SB600125 (JNK inhibitor; IC50 = 40-90 nM) were purchased from Santa Cruz Biotechnology, SCBT; Santa Cruz, CA).
TGF-b1 Enzyme Immunoassay
The immunoassay for the determination of TGF-b1 was obtained from Enzo Life Sciences AG (Lausen, Switzerland). Emdogain was diluted to give 1 mg EMD/ml and processed to obtain a bioactive form that can be detected by the assay. In brief, twenty mL of 1N HCl were added to 100 mL EMD, and after ten minutes neutralized with 20 mL 1.2 N NaOH/0.5 M HEPES. These samples were subjected to immunoassay and TGF-b1 concentration was calculated based on a calibration curve.
Oil Red O Staining
Cells were fixed with 10% neutral buffered formalin, washed with 60% isopropanol, and stained with Oil Red O (0.5%; Sigma). Cells were rinsed several times with tap water and subjected to microscopic analysis and were photographed.
Gene Expression Analysis
Cellular RNA was isolated using an RNAqueous-Micro Kit containing DNAse I (Ambion, Life Technologies). RNA was quantified (Nanodrop 2000c; Thermo Scientific, Waltham, MA, USA). Reverse transcription (RT) was performed with a highcapacity cDNA RT-kit (Applied Biosystems, Foster City, CA) and PCR was done with TaqManH universal PCR Master Mix (Applied Biosystems) on a 7500 Real-Time PCR System (Applied Biosystems). For screening, the TaqManH Array Mouse Lipid Regulated Genes 96-well Plate (Applied Biosystems), a panel of assays for genes controlling sterol metabolism, fatty acid metabolism, lipid droplet, and transcription factors was used. Further probes were obtained from the TaqManH Gene Expression Assays service (Applied Biosystems, Mm01184322_m1 PPARc; Mm00521864_m1
Ltc4s; Mm00445878_m1 Fabp4; Mm00432403_m1
Cd36; Mm01192932_g1 CTGF; Mm01250458_m1 Alox15). For the expression of TGF-b, we used designed primers (forward tggagcaacatgtggaactc; reverse gtcagcagccggttacca) and SYBR Green as detection signal. The mRNA levels were calculated by normalizing to the housekeeping gene beta actin using the DCt method.
Western Blot Analysis
For phospho-Smad3 staining, 3T3-L1 cells were washed with phosphate buffered saline, serum-starved for over night and then treated with EmdogainH and TGF-b for 1 hours. For PPARc staining, 3T3-L1 cells were grown in adipogenic medium with and without EmdogainH for three days. Cells were lysed in SDS-buffer containing protease inhibitors. Cell extracts were separated by SDS-PAGE and transferred onto nitrocellulose membranes. Membranes were blocked in a supplied buffer (LI-COR Biosciences; Lincoln, NE). Binding of the antibody raised against phospho-Smad3 (Ser423/425) (Cell Signaling Technology, Danvers, MA), PPARc (E-8) and b-actin (C-4) (both SCBT) were detected with the appropriate secondary antibody directly labeled with near-infrared dyes and detected with the appropriate imaging system (LI-COR Biosciences; Lincoln, NE).
Transfection with siRNA
CTGF siRNA, mock siRNA and the transfection agent were purchased from SCBT. The transfection protocol was followed according to the instructions of the manufacturer. Inhibition efficacy was determined by Western blot analysis for CTGF. Transfected cells were exposed to EmdogainH at 100 ng/ml and TGF-b at 10 ng/ml in serum-free medium for 24 hours. Gene expression analysis was performed targeting PPARc. Transfected cells were also tested for their potential to provoke Oil Red O staining of 3T3-L1 cells in the presence of EmdogainH and TGFb.
Statistical Analysis
Experiments were repeated at least twice and data are reported as the mean and standard deviation. ANOVA and hoc testing were used for analysis. Statistical significance was established at P,0.05.
Results
EmdogainH Inhibits 3T3-L1 Adipocyte Differentiation
To investigate the impact of EmdogainH on adipocyte differentiation, we determined the accumulation of intracellular lipids. The 3T3-L1 cells accumulated lipid droplets within 5 days among treatment with the adipogenic medium. Treatment of 3T3-L1 cells with EmdogainH almost completely suppressed the formation of lipid droplets ( Figure 1A,B) . Based on the TaqManH array, EmdogainH considerably (,4-fold) decreased the mRNA level of PPARc, FABP4, CD36, and LTC4s (Table 1 ). The data were confirmed by the traditional RT-PCR approach ( Figure 1C ). The decrease of PPARc by EmdogainH was also confirmed at the protein level ( Figure 1D ).
EmdogainH and TGF-b also increase CTGF in 3T3-L1 cells ( Figure 1D ). The TaqManH array further revealed a 20-fold reduction of 15-lipogygenase (Alox15), which is a key enzyme converting arachidonic acid to the biologically active 15(S)-HETE [29] . However, this finding could not be confirmed by the traditional RT-PCR approach. Together, the data show that EmdogainH inhibits adipocyte differentiation of 3T3-L1 cells in vitro.
Rosiglitazone and Indomethacin Failed to Rescue the Adipocyte Differentiation of EmdogainH-treated Cells
To understand if the inhibitory effect of EmdogainH can be overcome by manipulation of PPARc, rescue experiments with the supplementation of indomethacin, known to increase PPARc expression [29] , and rosiglitazone, an agonist for PPARc [30] , were performed. As shown in Figure 2 , indomethacin and rosiglitazone, either alone or in combination, failed to provoke the formation of lipid droplets in 3T3-L1 cells treated with EmdogainH. Overall, the data show that targeting PPARc by rosiglitazone and indomethacin cannot overcome the inhibitory effect of EmdogainH on adipogenic differentiation.
SB-431542, an Inhibitor of TGF-b RI Kinase Activity, Reversed the Inhibitory Effects of EmdogainH
To dissect the mechanism by which EmdogainH decreases adipogenic differentiation of 3T3-L1 cells, we used the potent and selective inhibitor of the TGF-b type I receptor activin receptorlike kinase ALK5 [31] . SB-431542 allowed the formation of lipid droplets in the presence of EmdogainH ( Figure 3A ). In line with these findings, SB-431542 reversed the inhibitory effects of EmdogainH on the mRNA level of PPARc in 3T3-L1 cells ( Figure 3B ). Also in primary murine fat-derived mesenchymal cells, SB-431542 reversed the inhibitory effects of EmdogainH and TGF-b on the expression of adipogenic genes (data not shown). Moreover, EmdogainH increased the mRNA levels of TGF-b by approximately 2-fold (data not shown). Immunoassay showed positive signals equivalent to approximately 100 ng/ml TGF-b1 in the commercial available Emdogain stock. In line with these data, EmdogainH and TGF-b increase phosphorylation of Smad3 in 3T3-L1 cells ( Figure 3C ). These results suggest that TGF-b signaling mediates the inhibitory effect of EmdogainH on adipogenic differentiation.
EmdogainH-induced TGF-beta Signaling Cascade Increases CTGF Expression
To further support the involvement of the TGF-b signaling cascade, we examined the effect of EmdogainH on the expression Figure 1 . EmdogainH inhibits 3T3-L1 adipocyte differentiation. The 3T3-L1 murine preadipocytes were incubated with growth medium containing 1-methyl-3-isobutyl-xanthine dexamethasone and insulin for 5 days in the presence of (A) propylene glycol alginate or (B) EmdogainH at dilutions equivalent to 100 mg/ml and stained for lipid droplets. (C) EmdogainH reduced the expression of lipid regulated genes and (D) also the signal of PPARc by Western blot analysis. EmdogainH, in contrast, increased the signal of CTGF. doi:10.1371/journal.pone.0071046.g001 Table 1 . The 3T3-L1 murine preadipocytes were incubated with growth medium containing 1-methyl-3-isobutyl-xanthine dexamethasone and insulin for 5 days in the presence of (A) propylene glycol alginate or (B) EmdogainH at dilutions equivalent to 100 mg/ml and subjected to a TaqManH Array for Mouse Lipid Regulated Genes. of CTGF, which is highly regulated by TGF-b, and can inhibit adipogenesis [16, 23] . EmdogainH substantially increased the expression of CTGF in 3T3-L1 cells. Consistent with the central role of the TGF-b signaling cascade, the presence of SB431542 but not SB600125 failed to substantially affect CTGF expression in 3T3-L1 cells ( Figure 4A ). Moreover, 3T3-L1 cells transfected with siRNA CTGF showed higher expression levels of PPARc when exposed to EmdogainH and TGF-b. Moreover, when transfected cells were exposed to Emdogain, a decrease of 38 kDa CTGF was observed by Western blot analysis 
EmdogainH after Heating at 96uC Maintains the Ability to Activate TGF-beta Signaling
Recent studies have shown that similar to TGF-b [28] , also heat-treatment of EmdogainH maintains a biological activity in vitro [32] . We therefore determined whether heating up to 96uC can alter the anti-adipogenic activity of EmdogainH. As shown in Figure 5A , heat-treated EmdogainH almost abolished the formation of lipid droplets in 3T3-L1 cells, again being reversed by SB431542. Moreover, heat-treated EmdogainH similarly changed expression of PPARc and CTGF compared to unheated EmdogainH ( Figure 5B ). SB431542 also reversed the effects of heat-treated EmdogainH on PPARc and CTGF expression (data not shown). These findings further support the role of EmdogainH activating TGF-b RI kinase activity.
3T3-L1 Cells Retain their Adipogenic Potential after Transient Exposure to EmdogainH
Although adipogenic differentiation of 3T3-L1 cells is suppressed in the presence of EmdogainH, it is possible that the cells regain the capacity to form adipocytes once EmdogainH has been removed. Consistent with this idea, 3T3-L1 cells that were exposed to EmdogainH or TGF-b for 24 and 72 hours maintain their capacity to form lipid droplets when cultivated in the adipogenic medium. These results demonstrate that the inhibition of adipogenic differentiation of 3T3-L1 cells by EmdogainH is transient ( Figure 6 ).
Discussion
Initial studies showed that EmdogainH can suppress in vitro adipogenic differentiation of C2C12 cells [8] , periodontal ligament fibroblasts [6] and palate fibroblasts (manuscript in preparation). TGF-b mediating at least part of the cellular responses to EmdogainH [11] [12] [13] [14] is a potent inhibitor of adipocyte differentiation in vitro [15, 16] . The existing data raised the possibility that the inhibitory effects of EmdogainH on adipogenic differentiation involves TGF-b. The in vitro evidence presented here demonstrates that blocking TGF-b RI kinase activity does indeed overcome the inhibitory effect of EmdogainH on adipogenic differentiation of 3T3-L1 cells. Our observation that the amount of CTGF mRNA, a TGF-b regulated inhibitor of adipogenesis [16, 23] , was also affected by EmdogainH, further supports the central role of TGF-b RI kinase activity in the suppression of adipogenic differentiation.
The present work is consistent with reports showing that EmdogainH strongly increases expression of CTGF in osteogenic cells [14] and data from microarray screening in periodontal ligament fibroblasts [33, 34] , and epithelial cells [35] . It is, however, important to note that in the present study, siRNA CTGF only partially reduced the expression levels of PPARc when exposed to EmdogainH and TGF-b, and that siRNA CTGF could not counteract the suppression of lipid formation by EmdogainH and TGF-b our observation basically supports the involvement of the TGF-b -CTGF autocrine pathway to mediate the inhibition of EmdogainH on adipogenesis, the definitive prove remains open. Thus, additional work will be required to determine whether complete blocking of CTGF can reverse the inhibitory effect of EmdogainH on adipogenic differentiation of mesenchymal progenitor cells in vitro.
The question arises about the source of TGF-b that mediates the inhibition of adipogenesis in vitro. In line with our findings that EmdogainH heated to 96uC maintains the respective biological activity supporting observations that TGF-b is stable under the same conditions [28] . Likewise, also heat-treatment of EmdogainH maintains a biological activity in vitro in other studies [32] . In support of this finding, the immunoassay detected .100 ng TGF-b1 in the Emdogain stock, resulting in at least 1 ng TGF-b1 in the working solution. Moreover, Emdogain caused the rapid phosphorylation of Smad3, which represents a mainly TGF-b signaling pathway. It is, then, possible that the inhibition of adipogenesis in our studies was the result of an intrinsic TGF-b activity of Emdogain, similar to other reports [10] . However, in vitro studies have suggested that EmdogainH can increase the expression of TGF-b is various cell types [10] . These previous findings are consistent with our data that TGF-b expression in 3T3-L1 cells is increased in response to Emdogain. Thus, there are two possible sources of TGF-b that can contribute to the overall inhibition of adipogenesis of mesenchymal cell in the present report.
Mesenchymal progenitors represent a population of cells within periodontal tissues and connective tissue grafts [5] [6] [7] . Since [38, 39] and the transplanted cells usually should not regain their adipogenic phenotype. Hence, EmdogainH might serve as a potential carrier suppressing the formation of fat cells. However, our findings that the inhibition of adipogenesis by EmdogainH is only transient indicate the complexity of the interpretation of our findings. The setting of 24 hours cell incubation was chosen because also in vivo, EmdogainH remains in place for a limited time period. Until now, ectopic models with bone substitutes and mesenchymal cells, not isolated from adipose tissue, either alone or together with EmdogainH, have not reported on the differentiation of the cells toward adipocytes [40, 41] . Albeit the present study and in vitro work from others [6, 8] argue for a strong anti-adipogenic effect of EmdogainH, the clinical relevance remains a matter of speculation.
JNK signaling can mediate EmdogainH effects in vitro [21] , and mitogen-activated protein kinase signaling is involved in TGF-bmediated inhibition of adipogenesis [20] . Our studies showed that blocking of JNK signaling failed to modulate the increased expression CTGF upon incubation of the cells with EmdogainH. Based on this observation we propose that the classical Smad signaling plays the key role in mediating the effect of EmdogainH in the present study. Future studies are required to reveal the possible activation of the Smad signaling in addition to siRNA Figure 5 . EmdogainH after heating at 966C maintains the ability to activate TGF-b signaling. (A) The 3T3-L1 murine preadipocytes were exposed to EmdogainH (100 mg/ml) or EmdogainH previously heated up to 96uC within a basal adipogenesis-inducing medium containing rosiglitazone and indomethacin for 5 days and lipid staining was performed. (B) 3T3-L1 cells were also exposed to normal or heat-treated EmdogainH for 18 hours in serum-free medium before the expression of PPARc and CTGF were determined. doi:10.1371/journal.pone.0071046.g005 Figure 6 . 3T3-L1 cells retain their adipogenic potential after transient exposure to EmdogainH. The 3T3-L1 murine preadipocytes were incubated for one day with growth medium containing EmdogainH (100 mg/ml) or TGF-b (10 ng/ml). Then the medium was replaced by basal adipogenesis-inducing medium containing rosiglitazone and indomethacin for 5 days and lipid staining was performed. doi:10.1371/journal.pone.0071046.g006 blocking of Smad 2 and Smad 3. Also the link of CTGF to signal via fibroblast growth factor (FGF) receptors-2 is relevant as bFGF is a antagonist for adipogenic differentiation of 3T3-L1 cells [42] . Future research perspectives might also reveal which size fraction of EmdogainH accounts true for the inhibition of adipogenesis.
In summary, we propose that the decreased adipogenesis by EmdogainH is caused by activation of TGF-b RI kinase in 3T3-L1 cells and is linked with a strong induction of CTGF expression. The present in vitro findings may serve as a primer for preclinical studies aiming to control adipogenic differentiation particularily in the field of regenerative dentistry.
